Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

被引：255

作者：

Apetoh, L. ^{[1
,2
,3
]}

Ladoire, S. ^{[1
,2
,3
]}

Coukos, G. ^{[4
]}

Ghiringhelli, F. ^{[1
,2
,3
]}

机构：

[1] INSERM, U866, Lipids Nutr Canc, Dijon, France

[2] Univ Bourgogne, Dept Med, Dijon, France

[3] Ctr Georges Francois Leclerc, Dept Oncol, Dijon, France

[4] Univ Lausanne, Dept Oncol, Lausanne, Switzerland

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷 / 09期

关键词：

chemotherapy; radiotherapy; anticancer immunity; immunomodulation; CD4 T cells; CD8 T cells; REGULATORY T-CELLS; METASTATIC BREAST-CARCINOMA; C-RECEPTOR POLYMORPHISMS; VIVO ANTITUMOR-ACTIVITY; NATURAL-KILLER-CELLS; DE-NOVO MALIGNANCY; TUMOR-CELLS; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; SUPPRESSOR-CELLS;

D O I：

10.1093/annonc/mdv209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade in different types of metastatic cancers. Such data underscore that immunotherapy is one of the most promising strategies for cancer treatment. In addition, preclinical studies provide evidence that some cytotoxic drugs have the ability to stimulate the immune system, resulting in anti-tumor immune responses that contribute to clinical efficacy of these agents. These observations raise the hypothesis that the next step for cancer treatment is the combination of cytotoxic agents and immunotherapies. The present review aims to summarize the immune-mediated effects of chemotherapeutic agents and their clinical relevance, the biological and clinical features of immune checkpoint blockers and finally, the preclinical and clinical rationale for novel therapeutic strategies combining anticancer agents and immune checkpoint blockers.

引用

页码：1813 / 1823

页数：11

共 166 条

[31]

The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation [J].

Demaria, Sandra ;

Pilones, Karsten A. ;

Vanpouille-Box, Claire ;

Golden, Encouse B. ;

Formenti, Silvia C. .

RADIATION RESEARCH, 2014, 182 (02) :170-181

[32]

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment [J].

Demaria, Sandra ;

Pilones, Karsten A. ;

Formenti, Silvia C. ;

Dustin, Michael L. .

ONCOIMMUNOLOGY, 2013, 2 (03)

[33]

Role of T lymphocytes in tumor response to radiotherapy [J].

Demaria, Sandra ;

Formenti, Silvia C. .

FRONTIERS IN ONCOLOGY, 2012, 2

[34]

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody [J].

Dewan, M. Zahidunnabi ;

Galloway, Ashley E. ;

Kawashima, Noriko ;

Dewyngaert, J. Keith ;

Babb, James S. ;

Formenti, Silvia C. ;

Demaria, Sandra .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5379-5388

[35]

Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype [J].

Ding, Zhi-Chun ;

Blazar, Bruce R. ;

Mellor, Andrew L. ;

Munn, David H. ;

Zhou, Gang .

BLOOD, 2010, 115 (12) :2397-2406

[36]

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer [J].

Disis, Mary L. ;

Wallace, Danelle R. ;

Gooley, Theodore A. ;

Dang, Yushe ;

Slota, Meredith ;

Lu, Hailing ;

Coveler, Andrew L. ;

Childs, Jennifer S. ;

Higgins, Doreen M. ;

Fintak, Patricia A. ;

dela Rosa, Corazon ;

Tietje, Kathleen ;

Link, John ;

Waisman, James ;

Salazar, Lupe G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4685-4692

[37]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[38]

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

[39]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[40]

The three Es of cancer immunoediting [J].

Dunn, GP ;

Old, LJ ;

Schreiber, RD .

ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360

← 1 2 3 4 5 6 7 8 9 10 →